Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 2
2006 1
2007 2
2008 3
2009 2
2010 2
2011 2
2012 2
2014 2
2015 2
2016 3
2017 5
2018 13
2019 18
2020 23
2021 25
2022 30
2023 28
2024 29
2025 24
2026 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Results by year

Filters applied: . Clear all
Page 1
A journey through cannabidiol in Parkinson's disease.
Del-Bel E, Barros-Pereira N, Moraes RP, Mattos BA, Alves-Fernandes TA, Abreu LB, Nascimento GC, Escobar-Espinal D, Pedrazzi JFC, Jacob G, Milan BA, Bálico GG, Antonieto LR. Del-Bel E, et al. Int Rev Neurobiol. 2024;177:65-93. doi: 10.1016/bs.irn.2024.04.015. Epub 2024 Jun 29. Int Rev Neurobiol. 2024. PMID: 39029991 Review.
The results of preclinical trials using cannabidiol in models of Parkinson's disease are encouraging. Nevertheless, drawing firm conclusions on the therapeutic efficacy of cannabidiol for patients is challenging. ...Though, cannabidiol ho …
The results of preclinical trials using cannabidiol in models of Parkinson's disease are encouraging. Neverthele …
Short-Term Cannabidiol with delta-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
Liu Y, Bainbridge J, Sillau S, Rajkovic S, Adkins M, Domen CH, Thompson JA, Seawalt T, Klawitter J, Sempio C, Chin G, Forman L, Fullard M, Hawkins T, Seeberger L, Newman H, Vu D, Leehey MA. Liu Y, et al. Mov Disord. 2024 May;39(5):863-875. doi: 10.1002/mds.29768. Epub 2024 Mar 15. Mov Disord. 2024. PMID: 38487964 Free PMC article. Clinical Trial.
BACKGROUND: Cannabis use is frequent in Parkinson's disease (PD), despite inadequate evidence of benefits and risks. OBJECTIVE: The aim is to study short-term efficacy and tolerability of relatively high cannabidiol (CBD)/low delta-9-tetrahydrocannabin …
BACKGROUND: Cannabis use is frequent in Parkinson's disease (PD), despite inadequate evidence of benefits and risks. OB …
Cannabinoids in Treating Parkinson's Disease Symptoms: A Systematic Review of Clinical Studies.
Varshney K, Patel A, Ansari S, Shet P, Panag SS. Varshney K, et al. Cannabis Cannabinoid Res. 2023 Oct;8(5):716-730. doi: 10.1089/can.2023.0023. Epub 2023 May 30. Cannabis Cannabinoid Res. 2023. PMID: 37253174
Background: Parkinson's disease (PD) is a serious neurodegenerative condition impacting many individuals worldwide. There is a need for new non-invasive treatments of PD. Cannabinoids in the form of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (T …
Background: Parkinson's disease (PD) is a serious neurodegenerative condition impacting many individuals worldwide. The …
Cannabidiol in Parkinson's disease.
Rieder CR. Rieder CR. Braz J Psychiatry. 2020 Apr;42(2):126-127. doi: 10.1590/1516-4446-2019-0810. Epub 2020 Mar 16. Braz J Psychiatry. 2020. PMID: 32187321 Free PMC article. No abstract available.
Cannabidiol and Parkinson's disease: Investigating receptor interactions and their therapeutic implications.
Okrah EA, Allan C, Doblin MS, Annesley SJ. Okrah EA, et al. Pharmacol Ther. 2026 Jan;277:108943. doi: 10.1016/j.pharmthera.2025.108943. Epub 2025 Oct 27. Pharmacol Ther. 2026. PMID: 41161354 Review.
Cannabidiol (CBD) is one of the major active constituents among the several hundreds of compounds found in the cannabis plant. ...In preclinical studies it has shown to be effective, safe, and well-tolerated in mitigating the symptoms associated with Parkinson's …
Cannabidiol (CBD) is one of the major active constituents among the several hundreds of compounds found in the cannabis plant. ...In …
Potential role of cannabidiol in Parkinson's disease by targeting the WNT/beta-catenin pathway, oxidative stress and inflammation.
Vallée A, Vallée JN, Lecarpentier Y. Vallée A, et al. Aging (Albany NY). 2021 Apr 13;13(7):10796-10813. doi: 10.18632/aging.202951. Epub 2021 Apr 13. Aging (Albany NY). 2021. PMID: 33848261 Free PMC article. Review.
Parkinson's disease (PD) is a major neurodegenerative disease (ND), presenting a progressive degeneration of the nervous system characterized by a loss of dopamine in the substantia nigra pars compacta. ...This review focuses on the potential effects o …
Parkinson's disease (PD) is a major neurodegenerative disease (ND), presenting a progressive degeneration of the …
Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG. Crippa JAS, et al. Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):121-133. doi: 10.1007/s00406-019-00982-6. Epub 2019 Jan 31. Eur Arch Psychiatry Clin Neurosci. 2019. PMID: 30706171 Review.
Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. ...The pharmacological treatment for these symptoms is limited in efficacy and induce sign …
Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, …
The Pharmacological Case for Cannabigerol.
Nachnani R, Raup-Konsavage WM, Vrana KE. Nachnani R, et al. J Pharmacol Exp Ther. 2021 Feb;376(2):204-212. doi: 10.1124/jpet.120.000340. Epub 2020 Nov 9. J Pharmacol Exp Ther. 2021. PMID: 33168643 Free article. Review.
Medical cannabis and individual cannabinoids, such as delta9-tetrahydrocannabinol (delta9-THC) and cannabidiol (CBD), are receiving growing attention in both the media and the scientific literature. ...Studies indicate that CBG may have therapeutic potential in treating ne …
Medical cannabis and individual cannabinoids, such as delta9-tetrahydrocannabinol (delta9-THC) and cannabidiol (CBD), are receiving g …
Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders.
de Fátima Dos Santos Sampaio M, de Paiva YB, Sampaio TB, Pereira MG, Coimbra NC. de Fátima Dos Santos Sampaio M, et al. Basic Clin Pharmacol Toxicol. 2024 May;134(5):574-601. doi: 10.1111/bcpt.13997. Epub 2024 Mar 13. Basic Clin Pharmacol Toxicol. 2024. PMID: 38477419 Review.
The aim of this review was to provide an overview of cannabinoid effects on neurological disorders, such as epilepsy, multiple sclerosis and Parkinson's diseases, and discuss their possible mechanism of action, highlighting interactions with molecular targets and th …
The aim of this review was to provide an overview of cannabinoid effects on neurological disorders, such as epilepsy, multiple sclerosis and …
Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Junior NCF, Dos-Santos-Pereira M, Guimarães FS, Del Bel E. Junior NCF, et al. Neurotox Res. 2020 Jan;37(1):12-29. doi: 10.1007/s12640-019-00109-8. Epub 2019 Oct 22. Neurotox Res. 2020. PMID: 31637586 Review.
Parkinson's disease (PD) and L-DOPA-induced dyskinesia (LID) are motor disorders with significant impact on the patient's quality of life. ...In this way, phytocannabinoids and synthetic cannabinoids, such as cannabidiol (CBD), the principal non-psycho …
Parkinson's disease (PD) and L-DOPA-induced dyskinesia (LID) are motor disorders with significant impact on the patient …
201 results